Edition:
India

GlaxoSmithKline PLC (GSK.L)

GSK.L on London Stock Exchange

1,676.00GBp
22 Aug 2019
Change (% chg)

-9.00 (-0.53%)
Prev Close
1,685.00
Open
1,679.60
Day's High
1,686.40
Day's Low
1,667.80
Volume
8,074,399
Avg. Vol
6,921,982
52-wk High
1,749.40
52-wk Low
1,408.80

Latest Key Developments (Source: Significant Developments)

GSK Completes Transaction With Pfizer For New JV
Thursday, 1 Aug 2019 

Aug 1 (Reuters) - GlaxoSmithKline PLC ::GLAXOSMITHKLINE PLC - GSK COMPLETES TRANSACTION WITH PFIZER FOR NEW JV.GLAXOSMITHKLINE PLC - COMPLETED ITS TRANSACTION WITH PFIZER TO COMBINE THEIR CONSUMER HEALTHCARE BUSINESSES INTO A WORLD-LEADING JOINT VENTURE.GSK - JOINT VENTURE WILL FOCUS ON COMPLETING INTEGRATION OF TWO BUSINESSES, WHICH IS EXPECTED TO REALISE ANNUAL COST SAVINGS OF £0.5BN BY 2022.  Full Article

Pfizer Announces Closing Of Joint Venture With GlaxoSmithKline
Thursday, 1 Aug 2019 

Aug 1 (Reuters) - Pfizer Inc ::PFIZER ANNOUNCES CLOSING OF JOINT VENTURE WITH GLAXOSMITHKLINE TO CREATE A PREMIER GLOBAL CONSUMER HEALTHCARE COMPANY.  Full Article

Pfizer Reports Second-Quarter 2019 Results
Monday, 29 Jul 2019 

July 29 (Reuters) - Pfizer Inc ::PFIZER REPORTS SECOND-QUARTER 2019 RESULTS.Q2 ADJUSTED EARNINGS PER SHARE $0.80.Q2 EARNINGS PER SHARE $0.89.Q2 EARNINGS PER SHARE ESTIMATE $0.75 -- REFINITIV IBES DATA.ANNOUNCES REVERSE MORRIS TRUST TRANSACTION TO COMBINE UPJOHN AND MYLAN, CREATING A NEW GLOBAL PHARMACEUTICAL COMPANY.UPDATED 2019 FINANCIAL GUIDANCE.SEES FY REVENUE $50.5 TO $52.5 BILLION.SECOND-QUARTER 2019 UPJOHN REVENUES TOTALED $2.8 BILLION, DOWN 7% OPERATIONALLY.SEES 2019 ADJUSTED EPS OF $2.76 PER SHARE TO $2.86 PER SHARE.SECOND-QUARTER 2019 REVENUES TOTALED $13.3 BILLION, A DECREASE OF $203 MILLION, OR 2%, COMPARED TO PRIOR-YEAR QUARTER.PFIZER - DUE TO PROPOSED TRANSACTION BETWEEN CO AND MYLAN, CO'S Q2 EARNINGS CONFERENCE CALL WITH INVESTMENT ANALYSTS HAS BEEN RESCHEDULED FOR TODAY.Q2 REVENUE VIEW $13.40 BILLION -- REFINITIV IBES DATA.FY2019 EARNINGS PER SHARE VIEW $2.91, REVENUE VIEW $53.28 BILLION -- REFINITIV IBES DATA.SECOND-QUARTER 2019 BIOPHARMA REVENUES TOTALED $9.6 BILLION, UP 6% OPERATIONALLY.SECOND-QUARTER 2019 UPJOHN REVENUES TOTALED $2.8 BILLION, DOWN 7% OPERATIONALLY.REVENUES FOR UPJOHN IN CHINA FOR FULL YEAR ARE EXPECTED TO GROW BY LOW-TO-MID-SINGLE-DIGITS OPERATIONALLY.PFIZER-SEES NEGATIVE IMPACT OF $1.5 BILLION TO 2019 REVENUE & NEGATIVE IMPACT OF $0.03 TO 2019 ADJUSTED EPS DUE TO PENDING FORMATION OF CONSUMER HEALTHCARE JV.  Full Article

GlaxoSmithKline Posts Q2 Adjusted EPS 30.5 Pence
Wednesday, 24 Jul 2019 

July 24 (Reuters) - Glaxosmithkline Plc ::Q2 ADJUSTED EPS ROSE 9 PERCENT TO 30.5 PENCE.QTRLY TOTAL EPS 19.5P.2019 ADJUSTED EPS GUIDANCE IMPROVED TO EXPECTED DECLINE OF -3% TO -5% AT CER FROM -5% TO -9%.19P DIVIDEND DECLARED FOR QUARTER; CONTINUE TO EXPECT 80P FOR FY19.QTRLY GROUP SALES £7.8 BILLION, +7% AER, +5% CER.QTRLY ADJUSTED EPS 30.5P.NEW GUIDANCE REFLECTS IMPROVED OPERATING PERFORMANCE, LOWER INTEREST EXPENSE, ONE-OFF BENEFIT TO SHARE OF AFTER TAX PROFITS OF ASSOCIATES IN Q1.QTRLY PHARMACEUTICALS SALES £4.3 BILLION, +2% AER, -1% CER.POSITIVE CLINICAL DATA RECEIVED SO FAR THIS YEAR OFFER SIGNIFICANT NEW OPPORTUNITIES FOR PRODUCTS IN ONCOLOGY, HIV, RESPIRATORY.QTRLY VACCINES SALES £1.6 BILLION, +26% AER, +23% CER.SHINGRIX RECORDED SALES OF £386 MILLION IN THE QUARTER, DRIVEN BY CONTINUED STRONG UPTAKE IN THE US.QTRLY CONSUMER HEALTHCARE SALES £1.9 BILLION, +5% AER, +4% CER.IF EXCHANGE RATES HOLD AT CLOSING RATES ON 30 JUNE FOR REST OF 2019, ESTIMATED POSITIVE IMPACT ON 2019 STERLING TURNOVER GROWTH TO BE ABOUT 2%.EXPECT TO COMPLETE JOINT VENTURE WITH PFIZER SHORTLY.QTRLY TURNOVER INCREASED 5% CER WITH CER GROWTH DELIVERED BY VACCINES, CONSUMER HEALTHCARE PARTIALLY OFFSET BY DECLINE IN PHARMACEUTICALS.QTRLY HIV SALES £1.2 BILLION +2% AER, -2% CER.QTRLY SALES OF ESTABLISHED PHARMACEUTICALS DECLINED 6% AER, 7% CER TO £2,138 MILLION INCLUDING IMPACT OF LOSS OF EXCLUSIVITY OF ADVAIR.TOTAL MAJOR RESTRUCTURING CHARGES INCURRED IN QUARTER WERE £309 MILLION (Q2 2018: £158 MILLION).  Full Article

GSK Says Co To Announce Collaboration With Lyell Immunopharma
Wednesday, 24 Jul 2019 

July 24 (Reuters) - GlaxoSmithKline PLC ::SAYS "SHINGRIX HAD ANOTHER STANDOUT QUARTER" - CONF CALL.SAYS MORE THAN DOUBLED THE NUMBER OF ASSETS IN ONCOLOGY OVER THE LAST 12 MONTHS - MEDIA CALL.HAL BARRON SAID ON THE MEDIA CALL THAT THE COMPANY WILL ANNOUNCE A COLLABORATION WITH LYELL IMMUNOPHARMA.GSK, WITH RESPECT TO BREXIT, SAYS NOTHING HAS REALLY CHANGED AND WE CONTINUE TO PREPARE FOR ALL SCENARIOS - CONF CALL.SAYS NO-DEAL BREXIT WOULD BE A BAD SCENARIO - CONF CALL.GSK CEO, WITH RESPECT TO BREXIT, SAYS STAND READY TO WORK WITH BRITISH GOVERNMENT - CONF CALL.  Full Article

GSK Names Jonathan Symonds As Non-Executive Chairman Of Board Of Directors
Wednesday, 24 Jul 2019 

July 24 (Reuters) - GlaxoSmithKline PLC ::GLAXOSMITHKLINE PLC HSBC HOLDINGS PLC - NON-EXECUTIVE CHAIRMAN.GLAXOSMITHKLINE PLC - GLAXOSMITHKLINE PLC APPOINTS JONATHAN SYMONDS AS NON-EXECUTIVE CHAIRMAN OF BOARD OF DIRECTORS.GLAXOSMITHKLINE - JONATHAN SYMONDS WILL SUCCEED SIR PHILIP HAMPTON AS NON-EXECUTIVE CHAIRMAN OF GSK BOARD.  Full Article

HSBC Says Jonathan Symonds To Reitre As Independent Non-Executive Director
Wednesday, 24 Jul 2019 

July 24 (Reuters) - 0005.HK <0005.HK>::DIRECTOR DECLARATION AND RETIREMENT OF DIRECTOR.JONATHAN SYMONDS, INDEPENDENT NON-EXECUTIVE DIRECTOR OF HSBC HOLDINGS PLC ( "COMPANY"), HAS BEEN APPOINTED AS NON-EXECUTIVE CHAIRMAN OF GSK.  Full Article

GSK Poised To Name Jonathan Symonds As Its Next Chairman- Bloomberg
Sunday, 14 Jul 2019 

July 14 (Reuters) - :GLAXOSMITHKLINE PLC IS POISED TO NAME JONATHAN SYMONDS AS ITS NEXT CHAIRMAN- BLOOMBERG, CITING A SOURCE.  Full Article

GSK Says ViiV Switch Study Shows 2DR As Effective As 3DR
Wednesday, 10 Jul 2019 

July 10 (Reuters) - GlaxoSmithKline PLC ::GLAXOSMITHKLINE PLC - VIIV SWITCH STUDY SHOWS 2DR AS EFFECTIVE AS 3DR.GLAXOSMITHKLINE PLC - PHASE III HIV STUDY MEETS PRIMARY ENDPOINT.GSK- STUDY SHOWED ABILITY TO CONTROL HIV-1 WITH REGIMEN OF DOLUTEGRAVIR+LAMIVUDINE IN VIRALLY SUPPRESSED PATIENTS SWITCHING FROM 3-DRUG REGIMEN.GLAXOSMITHKLINE PLC - STUDY MET ITS PRIMARY ENDPOINT FOR NON-INFERIORITY.GLAXOSMITHKLINE PLC - SAFETY RESULTS FOR 2DR OF DOLUTEGRAVIR PLUS LAMIVUDINE WERE CONSISTENT WITH PRODUCT LABELLING FOR MEDICINES.GSK - NO PATIENTS MET CONFIRMED VIROLOGIC WITHDRAWAL CRITERIA OR DEVELOPED TREATMENT RESISTANCE IN DOLUTEGRAVIR PLUS LAMIVUDINE ARM OF STUDY.  Full Article

Springworks Therapeutics Announces Global Clinical Collaboration With GlaxoSmithKline
Thursday, 27 Jun 2019 

June 27 (Reuters) - :SPRINGWORKS THERAPEUTICS ANNOUNCES GLOBAL CLINICAL COLLABORATION WITH GLAXOSMITHKLINE TO EVALUATE NIROGACESTAT IN COMBINATION WITH BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA.SPRINGWORKS - GLAXOSMITHKLINE WILL SPONSOR & CONDUCT ADAPTIVE PHASE 1B STUDY TO EVALUATE SAFETY, TOLERABILITY & PRELIMINARY EFFICACY OF COMBINATION.SPRINGWORKS THERAPEUTICS - GLAXOSMITHKLINE WILL ASSUME ALL DEVELOPMENT COSTS ASSOCIATED WITH STUDY.SPRINGWORKS THERAPEUTICS - GLAXOSMITHKLINE, CO WILL ALSO FORM JOINT DEVELOPMENT COMMITTEE TO MANAGE CLINICAL STUDY.  Full Article

Photo

GSK's long acting HIV injection gets boost from study

GlaxoSmithKline's experimental HIV injection is as effective when given every other month as monthly, according to a study, a convenience that could help the British drugmaker in its battle against a rival drug from Gilead Sciences.GSK's two-drug injection was as effective as a monthly dose of the same regimen in maintaining viral suppression at 48 weeks in a late-stage study, said ViiV Healthcare, GSK's HIV unit.